Ipilimumab in Melanoma Patients with Brain Metastasis: A Retrospective Multicentre Evaluation of Thirty-eight Patients
Marios Konstantinou(Université Toulouse III - Paul Sabatier), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), Caroline Gaudy‐Marqueste(Aix-Marseille Université), Sylvie Thellier, Thomas Jouary(Hôpital Saint-André), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Jean‐Jacques Grob(Aix-Marseille Université), C. Templier, B. Guillot(Université de Montpellier), Laurent Mortier, C. Paul(Université Fédérale de Toulouse Midi-Pyrénées), Christophe Bédane, Lilia Sakji, M.-A. Richard, Catherine Girard(Université du Québec à Chicoutimi)
Cited by 44
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k